Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05670587 · ClinicalTrials.gov registry record · NA
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
A NA study of Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 13
- Study locations
NCT05670587 is a NA study of Pulmonary Fibrosis that has completed, run by Boehringer Ingelheim. The registered enrollment target is 53 participants, below the 886-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (94% lower). The trial reports 13 study locations across 5 states.
The verdict
NCT05670587, a NA study of Pulmonary Fibrosis, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis). The purpose of this study is to better understand coughing in people with pulmonary fibrosis. To do this, a wearable cough monitor called Strados Remote Electronic Stethoscope Platform (RESP) is used. This device will measure how often and how forceful coughing is in people with pulmonary fibrosis. All participants in the study get the device. It is placed on their skin over the chest. Participants are in the study for 3 months. During this time, they visit the study site 2 to 3 times. 4 visits are done at the participant's home by video call with the site staff. During the study, the device measures coughing over 24 hours. This is done on 4 days. Participants fill in questionnaires about their coughing and doctors regularly check participant's lung function. A breathing test that measures how well the lungs are working is performed both in the office and during home visits. The doctors also regularly check participants' health and take note of any unwanted effects. This study will also record patients' experiences using the cough monitor and video assisted breathing tests at visits 3, 4, 5 and 6 at home.
Conditions Studied
Interventions
- DEVICE A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Study Locations (13)
Other
- Aalst - HOSP Onze-Lieve-Vrouw - Aalst
- Jessa Ziekenhuis - Campus Virga Jesse - Hasselt
- Kortrijk - HOSP AZ Groeninge Kennedylaan - Kortrijk
- Roeselare - HOSP AZ Delta - Roeselare
- Universitätsklinikum Freiburg - Freiburg im Breisgau
- Universitätsklinikum Jena - Jena
- Rijnstate Hospital - Arnhem
- Amphia Ziekenhuis - Breda
- Erasmus Medisch Centrum - Rotterdam
Colorado
- Critical Care, Pulmonary and Sleep Associates - Lakewood
Nevada
- Renown Regional Medical Center - Reno
North Carolina
- Southeastern Research Center - Winston-Salem
South Carolina
- Lowcountry Lung and Critical Care - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2024-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05670587
The ClinicalTrials.gov registry entry for NCT05670587 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 886-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (94% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection is the first listed.
NCT05670587 reports 13 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Nevada.
Frequently Asked Questions
What is clinical trial NCT05670587 about?
NCT05670587 is a clinical study titled "A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device". This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis). The purpose of this study is to better understand coughing in people with pulmonary fibrosis. To do this, a wearable cough monitor called Strados Re...
What is the current status of trial NCT05670587?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2023-01-16. Estimated completion is 2024-03-07.
What conditions does trial NCT05670587 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis.
What interventions are being tested in trial NCT05670587?
The interventions under investigation include: A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection (DEVICE).
Who is sponsoring clinical trial NCT05670587?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05670587 being conducted?
This trial has 13 study locations across Colorado, Nevada, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
COMPLETED · NA
-
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
COMPLETED · NA
-
Advanced Imaging for Pulmonary Fibrosis
RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.